{"id":"NCT00264550","sponsor":"Centocor, Inc.","briefTitle":"An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Subjects With ActiveRheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2007-09","completion":"2012-05","firstPosted":"2005-12-13","resultsPosted":"2014-03-21","lastUpdate":"2014-04-29"},"enrollment":444,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Golimumab 100 mg","otherNames":[]},{"type":"DRUG","name":"Golimumab 50 mg","otherNames":[]},{"type":"DRUG","name":"Methotrexate","otherNames":[]},{"type":"DRUG","name":"Placebo injection","otherNames":[]},{"type":"DRUG","name":"Placebo capsules","otherNames":[]}],"arms":[{"label":"Group 1: Placebo + Methotrexate","type":"PLACEBO_COMPARATOR"},{"label":"Group 2: Golimumab 100 mg + Placebo","type":"EXPERIMENTAL"},{"label":"Group 3: Golimumab 50 mg + Methotrexate","type":"EXPERIMENTAL"},{"label":"Group 4: Golimumab 100 mg + Methotrexate","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of golimumab, alone or in combination with methotrexate (MTX), as compared to methotrexate alone in rheumatoid arthritis (RA) patients who have active rheumatoid arthritis despite treatment with MTX.","primaryOutcome":{"measure":"Number of Participants Who Achieved American College of Rheumatology (ACR) 20 Response at Week 14","timeFrame":"Week 14","effectByArm":[{"arm":"Group 1: Placebo + Methotrexate","deltaMin":44,"sd":null},{"arm":"Group 2: Golimumab 100 mg + Placebo","deltaMin":59,"sd":null},{"arm":"Group 3: Golimumab 50 mg + Methotrexate","deltaMin":49,"sd":null},{"arm":"Group 4: Golimumab 100 mg + Methotrexate","deltaMin":50,"sd":null},{"arm":"Combined Golimumab + Methotrexate","deltaMin":99,"sd":null}],"pValues":[{"comp":"OG000 vs OG004","p":"<0.001"},{"comp":"OG000 vs OG002","p":"0.001"},{"comp":"OG000 vs OG003","p":"<0.001"},{"comp":"OG000 vs OG001","p":"0.059"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":50,"countries":["United States","Argentina","Australia","Canada","Chile","Germany","Hungary","Mexico","New Zealand","Poland","South Korea","Taiwan"]},"refs":{"pmids":["30412238","28606966","27803138","27696724","24757132","23678153","22505702","21083889"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":105},"commonTop":["Upper Respiratory Tract Infection","Nasopharyngitis","Bronchitis","Cough","Pharyngitis"]}}